Orgaran (danaparoid sodium)
The antithrombotic agent danaparoid sodium (Orgaran, formerly Org 10172 and Lomoparan) is a mixture of the following glycosaminoglycans:
- Heparan sulphate 83%
- Dermatan sulphate 12%
- Chondroitin sulphate 5% Orgaran exerts its major anticoagulant effect by catalysing inactivation of factor Xa by Antithrombin.
It also has some anti-Thrombin (IIa) effect but the ratio of anti-Xa to anti-IIa effect is greater than 28:1.
Orgaran is a non-heparin of proven efficacy in thrombotic disorders and is approved and available for use in the UK for the treatment of HIT complicated by thromboembolism.
Orgaran has been recommended as a heparin substitution therapy under the guidelines established by the ACCP for the management of HIT (Recommendation Grade 1B)18.
Take control; reduce mortality24.
Treatment algorithm
Contact information
Organon Laboratories Ltd
Cambridge Science Park
Milton Road
Cambridge
CB4 0FL
Telephone 01223 432700
Fax 01223 424368
(www.organon.co.uk)
Cambridge Science Park
Milton Road
Cambridge
CB4 0FL
Telephone 01223 432700
Fax 01223 424368
(www.organon.co.uk)
© 2008 Organon Laboratories. All rights reserved. Date of prep. November 2008. Item code: 09847G